DexCom Inc $ 411.26 9.08 (2.26%)
Volume:
389,228
Avg Vol (1m):
748,020
Market Cap $:
39.23 Bil
Enterprise Value $:
38.49 Bil
P/E (TTM):
187.11
P/B:
28.88
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.42 | ||
| Equity-to-Asset | 0.38 | ||
| Debt-to-Equity | 1.3 | ||
| Debt-to-EBITDA | 5.33 | ||
| Interest Coverage | 3.92 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 12.05 | ||
| Beneish M-Score | -2.5 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 15.09 | ||
| Net Margin % | 11.93 | ||
| ROE % | 22.14 | ||
| ROA % | 8.11 | ||
| ROC (Joel Greenblatt) % | 56.09 | ||
| 3-Year Revenue Growth Rate | 32.6 |
DXCM
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 187.11 | ||
| Forward PE Ratio | 122.78 | ||
| PE Ratio without NRI | 187.11 | ||
| Price-to-Owner-Earnings | 267.47 | ||
| PB Ratio | 28.88 | ||
| PS Ratio | 22.44 | ||
| Price-to-Free-Cash-Flow | 184.93 | ||
| Price-to-Operating-Cash-Flow | 97.98 | ||
| EV-to-EBIT | 140.06 | ||
| EV-to-EBITDA | 116.54 | ||
| EV-to-Revenue | 22.42 | ||
| Current Ratio | 7.58 | ||
| Quick Ratio | 7.17 | ||
| Days Inventory | 78.43 | ||
| Days Sales Outstanding | 63.07 | ||
| Days Payable | 63.9 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 29.27 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 21.51 | ||
| Price-to-Median-PS-Value | 1.65 | ||
| Price-to-Graham-Number | 15.61 | ||
| Earnings Yield (Greenblatt) % | 0.71 |